| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 14687148 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 339 journal articles in the PubMed database | Email to a friend | | |
| Lichtenstein GR, Yan S, Bala M, et al.
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. [Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial]
Am J Gastroenterol 2004 Jan; 99(1):91-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Rutgeerts P, Feagan BG, Lichtenstein GR, et al.
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Gastroenterology 2004 Feb; 126(2):402-13.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Loftus EV, Feagan BG, Colombel JF, et al.
Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial. [JOURNAL ARTICLE]
Am J Gastroenterol 2008 Oct 3.
Abstract | Full Citation | | Thia KT, Sandborn WJ, Lewis JD, et al.
Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease. [JOURNAL ARTICLE]
Am J Gastroenterol 2008 Sep 11.
Abstract | Full Citation | Find Related Articles | | Hanauer SB, Feagan BG, Lichtenstein GR, et al.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Lancet 2002 May 4; 359(9317):1541-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Smith JP, Stock H, Bingaman S, et al.
Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. [JOURNAL ARTICLE]
Am J Gastroenterol 2007 Jan 11.
Abstract | Full Citation | Find Related Articles | | Ghosh S, Goldin E, Gordon FH, et al.
Natalizumab for active Crohn's disease. [Clinical Trial, Journal Article, Randomized Controlled Trial]
N Engl J Med 2003 Jan 2; 348(1):24-32.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Targan SR, Feagan BG, Fedorak RN, et al.
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. [Journal Article, Research Support, Non-U.S. Gov't]
Gastroenterology 2007 May; 132(5):1672-83.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Sandborn WJ, Hanauer S, Loftus EV, et al.
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
Am J Gastroenterol 2004 Oct; 99(10):1984-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
